This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Biothrax
- Generic Name
- Anthrax vaccine
- DrugBank Accession Number
- DB11003
- Background
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium [FDA Label].
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Anthrax vaccine adsorbed
- Bacillus anthracis inactivated antigen
- Bacillus anthracis strain V770-NP1-R antigen
- Bacillus anthracis strain V770-NP1-R antigens
- Bacillus anthracis strain V770-NP1-R filtrate (attenuated) antigen
- Bacillus anthracis strain V770-NP1-R filtrate antigen
- External IDs
- RPA102
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Anthrax vaccine is combined with Abatacept. Acyclovir The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Anthrax vaccine. Adefovir dipivoxil The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Anthrax vaccine is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Anthrax vaccine is combined with Altretamine. Amantadine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Amantadine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image BioThrax Suspension 50 mcg / 0.5 mL Intramuscular; Subcutaneous Emergent Biodefense Operations Lansing Llc Not applicable Not applicable Canada 
BioThrax Injection, suspension 100 ug/1mL Intramuscular; Subcutaneous Emergent BioDefense Operations Lansing, LLC 1970-11-04 Not applicable US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 873OI62848
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911075
- 404774
- Wikipedia
- Anthrax_vaccine
- FDA label
- Download (363 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Bacillus Anthracis (Anthrax) 1 4 Completed Prevention Healthy Subjects (HS) 1 3 Completed Prevention Anthrax 1 3 Completed Treatment Anthrax 1 2 Completed Prevention Anthrax 3 2 Completed Treatment Anthrax 1 2 Terminated Prevention Bacillus Anthracis (Anthrax) 1 1 Completed Prevention Anthrax 1 1 Completed Prevention Anthrax Infection 1 1 Completed Prevention Anthrax / Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular; Subcutaneous Injection, suspension Intramuscular; Subcutaneous 100 ug/1mL Suspension Intramuscular; Subcutaneous 50 mcg / 0.5 mL Injection, suspension Intramuscular 50 mcg/dose - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:05 / Updated at June 12, 2020 17:42